Therapeutic drug for nonalcoholic fatty liver disease
A fatty liver disease, non-alcoholic technology, applied in drug combinations, viral peptides, pharmaceutical formulations, etc.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment
[0143]This example uses the mouse model of nonalcoholic steatohepatitis (NSAH) to evaluate the effect of hepalatide (L47) on the metabolic level and pathological changes of NASH, and to determine whether L47 can improve NASH lesions. Pharmacodynamic evaluation provides a reference.
[0144] 1. Experimental materials and methods
[0145] 1. Experimental materials
[0146] Hepalatide (L47); preparation method: Weigh the required L47 into a 15ml centrifuge tube, add the required volume of 1X PBS buffer, shake and shake well, and prepare it immediately.
[0147] Preparation method: preparation of PBS buffer mother solution:
[0148] Liquid A: 0.2M Na 2 HPO 4 : Weigh 71.6g Na 2 HPO 4 -12H 2 O, 8g NaCl, dissolved in 1000ml water;
[0149] Solution B: 0.2M NaH 2 PO 4 : Weigh 31.2g NaH 2 PO 4 -2H 2 O, 8g NaCl, dissolved in 1000ml water;
[0150] 20X PBS buffer preparation: mix 81ml of solution A and 19ml of solution B to make 100ml;
[0151] 1X PBS buffer preparation: T...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


